UOG (United One Group) Wins Three Prestigious Industry Awards at CES 2026 
LiveWorld Releases First-Ever AI Brand Reputation Index for Leading OTC Brands
Study highlights how AI tools like ChatGPT are shaping reputation and consumer perception of leading OTC brandsCAMPBELL, Calif. and NEW...
Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic
-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE)...
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis
The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitisTopline data expected in...
Visory Health Wins Gold at the 2025 Digital Health Awards
Award-winning health tech company brings prescription savings to over 38,700 pharmacies nationwideESTERO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Visory...
Processa Pharmaceuticals Provides Portfolio and Business Update
Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of...
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused...
H.H.C. Group Celebrates 30 Years of Industry Leadership in Healthcare Cost Containment
ROCKVILLE, Md., July 01, 2025 (GLOBE NEWSWIRE) -- H.H.C. Group (H.H.C.), a leader in reducing healthcare costs by providing high-quality...
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of...
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance...
Earth Science Tech, Inc. Qualifies for and Joins New OTCID Tier
Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic...
Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants
SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal...
Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio
Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO...
CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab
Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn’s ongoing Phase II CRC trial Dr. Benjamin Weinberg...
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for...
PetMed Express, Inc. Provides Update on Status of Fourth Quarter and FY 2025 Results and Form 10-K Filing
DELRAY BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (the “Company”) dba PetMeds and parent company of...
Vivos Therapeutics Receives Medicare Approval for VidaSleep™ Oral Appliance
Important Milestone Clears the Way for Millions of Medicare Beneficiaries with Sleep Apnea to Access Vivos’ Patented and FDA-Cleared Oral...
Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants
NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated...
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career...
Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC
Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation...
Aptose Upgraded to Trade on OTCQB Market
Aptose will trade under the ticker symbol APTOF and begin trading on OTCQB today, July 1stSAN DIEGO and TORONTO, July...